JUL 06, 2015 11:34 AM PDT

BRCA Breakthrough

While the BRCA2 gene is supposed to suppress tumors, its mutated form puts people at high risk for breast, ovarian and other cancers. Scientists from Yale University School of Medicine think they have found a molecule that is critical to the function of BRCA2. They think it could lead to potential drugs to break down the BRCA2 mutant's resistance to cancer treatment, as published in the journal Molecular Cell and reported in Medical News Today (http://www.medicalnewstoday.com/articles/296337.php).
If molecule helps mutant gene to function and resist chemotherapy, new drugs could be targeted against it.
While cancer cells need to repair DNA to survive, these cells are maintaining the integrity of "faulty" DNA, the researchers explain. According to the national Cancer Institute (NCI), BRCA1 and BRCA2 mutations account for 20 to 25 percent of hereditary breast cancers, 5 to 10 percent of all breast cancers and 15 percent of all ovarian cancers. Research has shown that breast and ovarian cancers involving BRCA1 and BRCA2 mutations develop earlier in life than their non-hereditary counterparts and that the mutations play a role in prostate and pancreatic cancers.

Chemotherapy drugs can be effective for fighting cancer in people with BRCA mutations, but the cancer can develop resistance to the drugs over time. While the researchers say that the BRCA proteins develop secondary mutations that continue to promote cancer growth, senior author Patrick Sung, a professor of molecular biophysics and biochemistry, thinks that drugs that interfere with DSS1 function could be developed and used with existing drugs to overcome this resistance, explaining, ""We can design specific targets for drug development only if we fully understand the key players and how they work in the pathway for repairing DNA breaks." Grants from the National Institutes of Health helped fund the study, which, according to the researchers, will help people to understand how cancer cells repair DNA breaks and thus pave to the way to developing new ways to counter resistance to chemotherapy.

A key molecule called co-factor DSS1 helps the BRCA2 gene to repair DNA, the researchers say. They believe that "DSS1 acts as a DNA mimic," and without it, BRCA2 mutations cannot do their job of repairing DNA, which is key to the survival of cancer cells."

The researchers establish the crucial role played by co-factor DSS1, without which the BRCA2 mutant is unable to fulfill its normal duty of DNA repair. Drugs that interfere with DSS1 function could be developed and used in conjunction with existing drugs like Astra Zeneca's Lynparza to overcome this resistance, Sung concludes (http://www.rdmag.com/news/2015/07/why-brca-gene-resists-cancer-treatment).
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Effective Treatment for Ulveal Melanoma
Uveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly h...
OCT 19, 2019
Cancer
OCT 19, 2019
Will a Capsule Do Away With Colon Cancer Screening Prep?
While the official colon cancer screening guidelines say people with an average risk for colon cancer should start to get screened starting at age 50, only...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Aspirin Usage Improves Liver Function After Embolization Treatment
Aspirin usage has been under scrutiny in recent research. But now, studies are bringing aspirin therapy in renewed light with its association in improving ...
OCT 19, 2019
Cancer
OCT 19, 2019
Antibiotic use associated with bowel cancer
From 2000–2010, global consumption of antibiotics rose by 35% up to 70 billion doses each year. Although doctors are more cautious to prescribe antib...
OCT 19, 2019
Immunology
OCT 19, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
OCT 19, 2019
Cancer
OCT 19, 2019
Scientists develop a single delivery immunotherapy threatment
Research published recently in Cell Stem Cell details the results from a new anticancer immunotherapy that uses invariant natural killer T (iNKT) cells. Th...
Loading Comments...